Terms: = Thyroid cancer AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132 AND Treatment
3 results:
1. PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating keap1 and inhibiting ferroptosis.
Wang Z; Li R; Hou N; Zhang J; Wang T; Fan P; Ji C; Zhang B; Liu L; Wang Y; Kong J; Yao Q; Duan J; Zhao G; Ling R; Zhang J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37380368
[TBL] [Abstract] [Full Text] [Related]
2. TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for treatment Selection.
Miyagawa-Hayashino A; Okada S; Takeda-Miyata N; Takashima Y; Yamada T; Takemura Y; Uchino J; Inoue M; Takayama K; Konishi E
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):313-320. PubMed ID: 33031101
[TBL] [Abstract] [Full Text] [Related]
3. Impact of Antioxidant Natural Compounds on the thyroid Gland and Implication of the keap1/Nrf2 Signaling Pathway.
Paunkov A; Chartoumpekis DV; Ziros PG; Chondrogianni N; Kensler TW; Sykiotis GP
Curr Pharm Des; 2019; 25(16):1828-1846. PubMed ID: 31267862
[TBL] [Abstract] [Full Text] [Related]
